The National Cancer Institute–sponsored STAR (Study of Tamoxifen and Raloxifene) trial brings good news for women, especially those at a higher–than–average risk of breast cancer.
Lilly's estrogen modulator, raloxifene (Evista), prevented breast cancer just as efficiently as the only drug approved by the Food and Drug Administration (FDA) for this purpose, tamoxifen. Both drugs reduced the risk of invasive breast cancer in postmenopausal women by about half (though tamoxifen—which has been used to treat breast cancer for over twenty–five years and to prevent it since 1998—also lowered the risk of non–invasive ductal lesions, while raloxifene did not). Moreover, Evista was safer than tamoxifen, with fewer clots, cataracts, and instances of uterine cancer.
Continue reading . . .